P2.101 Efflcacy and safety of preladenant, a novel A2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's disease von Hauser, R.A, Pourcher, E, Micheli, F, Mok, V, Onofrj, M, Huyck, S.B, Wolski, K.P, Cantillon, M

Volltext

P2.101 Efflcacy and safety of preladenant, a novel A 2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's disease von Hauser, R.A., Pourcher, E., Micheli, F., Mok, V., Onofrj, M., Huyck, S.B., Wolski, K.P., Cantillon, M.

Volltext

Auditing the efficacy of nutritional support identifies a subset of patients at risk von Chapman, D.J, Rowley, S.L, Wolski, J.M, Matson, L.E, Keating, K.P

Volltext